[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-organs-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-organs-disorder":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":15,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100518745",false,"NCT06034535","CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patient who requires allogeneic hematopoietic stem cell transplant, has no human leukocyte antigen (HLA)-matched sibling donor but has an HLA-haploidentical donor.\n* Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy\n* Karnofsky or Lansky performance status score ≥50\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom alternative treatment is deemed more appropriate by treating physician\n* Patients who are unlikely to benefit from haploidentical hematopoietic stem cell transplantation, e.g., terminal malignancy with multiorgan failure","ALL","18 Years",{"count":17,"type":18},23,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. The investigators shall evaluate the graft failure-free, graft-versus-host disease (GVHD)-free survival at one year, frequency of adverse events and post-transplant complications, and immunoreconstitution.",[24],"Hematopoietic Organs; Disorder","RECRUITING","2025-09-08",{"date":28,"type":29},"2025-09-15","ACTUAL",{"date":31,"type":29},"2023-09-01",{"date":33,"type":18},"2026-09",{"name":35,"class":36},"Hong Kong Children's Hospital","OTHER",1,{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":15,"enrollmentInfo":43,"targetDuration":4,"studyType":19,"phases":44,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":37},"100521897","NCT06075563","Total Lymphoid Irradiation as Conditioning for Pediatric Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Aged 0-18 years who requires allogeneic HSCT, has no human leukocyte antigen (HLA)-matched sibling donor but has an HLA-haploidentical donor.\n* Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy\n* Karnofsky or Lansky performance status score ≥50\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom alternative treatment is deemed more appropriate by treating physician\n* Patients who are unlikely to benefit from haploidentical hematopoietic stem cell transplantation, e.g., terminal malignancy with multiorgan failure",{"count":17,"type":18},[45],"NA","In this comparative study, the investigators aim to compare prospective pediatric patients who receive total lymphoid irradiation (TLI) using tomotherapy with age- and disease-matched controls who receive conventional total body irradiation (TBI) as part of conditioning for haploidentical hematopoietic stem cell transplantation (HSCT) for both malignant and non-malignant diseases. The investigators shall evaluate graft failure-free, graft-versus-host disease (GVHD)-free survival, overall survival, frequency of rejection, GVHD, relapse of malignancy, adverse effects and post-transplant immunoreconstitution.",[24],"2025-09-03",{"date":50,"type":29},"2025-09-10",{"date":52,"type":29},"2023-05-29",{"date":54,"type":18},"2026-12",{"name":35,"class":36},""]